Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

PODCAST EPISODE 213

Together, Roche and Biogen paid over $5.5 billion for gene therapy companies Spark and Nightstar. What does this mean for the emerging technology? Spark, of course, received FDA approval for Luxturna as a treatment for inherited retinal disease. But the drug isn’t Roche’s primary focus. Meanwhile, Nightstar’s clinical-stage products could give Biogen a second shot at a gene therapy portfolio after the company severed ties with AGTC in December. Could Biogen make a move to bulk up its ophthalmology offerings?